Japan’s Sawai has laid out its mid- and long-term ambitions in a new company business plan, spanning both its local and overseas operations.
Japan’s Sawai Pharmaceutical Co., Ltd. is aiming to capture a 20% share of its domestic generics market and achieve ¥400bn ($3.65bn) in group revenues by its 2030 financial year, according to a new long-term business plan, which also includes ambitions to almost double sales in its nascent US operations in that timeframe.
Financial results just reported by Sawai reveal group sales that increased by 2.6% to ¥187.2bn in the company’s financial year ended 31 March 2021, with growth of 6.6% to ¥153
Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.
Donald Trump’s executive order on most-favored-nation prescription drug pricing could provide positive opportunities for the off-patent industry, although US generics and biosimilars association the AAM suggested that the administration might do more good by focusing elsewhere.
With biosimilars playing an increasingly important role in Sandoz’s business, the firm’s first-quarter results call saw management lay out the latest key developments. Meanwhile, the company also addressed the issue of US tariffs, voicing optimism over both future developments as well as its ability to weather current measures.
Teva’s plans to generate net savings of $700m by 2027 have been described by the firm as a journey and not a destination, with the suggestion that “this era of cost efficiency, harmonization, frugality will continue.”
